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Abstract
Background: Maternal obesity is associated with adverse pregnancy outcomes and has lifelong negative implications
for offspring health. The Institute of Medicine recommends limited gestational weight gain (GWG) in obese women for
optimal maternal and infant outcomes. However, there is a gap regarding an effective and sustainable intervention
strategy to achieve this goal. The aim of the healthy mums and babies (HUMBA) demonstration trial is to assess
whether a multifaceted nutritional intervention and/or an oral probiotic treatment in obese pregnant women can
reduce excessive GWG and optimise pregnancy outcomes.
Methods and design: The study is a two by two factorial randomised controlled demonstration trial conducted in
Counties Manukau health region, New Zealand, a multi-ethnic region with a high prevalence of obesity. A total of 220
non-diabetic obese women with a singleton pregnancy will be recruited between 120 and 176 weeks. At recruitment,
women are randomised to receive either a culturally tailored multifaceted dietary intervention or routine dietary advice,
and either an oral probiotic or placebo capsule. Randomisation is undertaken via a web-based protocol, randomize.net,
with a 1:1 ratio using stratification by body mass index (BMI) category (BMI of 30–34.9 or BMI ≥35 kg/m2). The dietary
intervention includes 4 customised nutrition education visits by a trained community health worker combined
with motivational text messaging. Probiotic capsules consist of Lactobacillus rhamnosus GG and Bifidobacterium
lactis BB12 at a dose of 7 × 109 colony-forming units one per day until birth. Probiotic and placebo capsules are
identically pre-packed and labelled by a third party, and are prescribed in a double blinded fashion. Research
assessments are conducted at enrolment, 28 weeks, 36 weeks, at birth and at 5 months post-delivery. The primary
outcomes for the study are proportion of women with excessive GWG and infant birthweight.
Discussion: The HUMBA demonstration trial will assess the efficacy of a culturally tailored multifaceted dietary
intervention and probiotic treatment in limiting excessive GWG and optimising birthweight in a multiethnic
sample of obese pregnant women. If successful, either one or both of the interventions may be incorporated into
future studies powered to investigate important pregnancy outcomes.
Trial registration: Australian New Zealand Clinical Trials Registry registration number: ACTRN12615000400561,
Universal Trial Number: U1111-1155-0409. Date registered: 29th April 2015.
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Background
The global obesity epidemic is of increasing concern, with
671 million people in the world currently estimated to be
obese (body mass index (BMI) ≥ 30 kg/m2) [1]. Data from
the United States suggests that without effective interven-
tions, the rise in obesity will soon lead to reduction of life-
expectancy in high-income countries [2]. New Zealand
was rated the third most obese nation in the Organisation
for Economic Co-operation and Development countries in
2014 [3]. The latest New Zealand national health survey
showed that about 30% of women at child-bearing age
have a BMI of 30 or more, and the trend is increasing [4].
Of specific concern, the obesity rates are double in Māori
and Pacific adults and children compared with those from
European/other ethnic backgrounds [4], which highlights
ethnic inequalities in the obesity epidemic in New
Zealand.
Obese pregnant women have increased rates of most
pregnancy complications including gestational diabetes
(GDM), pre-eclampsia, caesarean section, and postpar-
tum haemorrhage [5]. Their infants are at higher risk of
congenital abnormalities, stillbirth, being born large for
gestational age (LGA) and consequential traumatic birth
and asphyxia [6, 7]. They are also at increased risk of a
range of neonatal complications, including respiratory
problems, sepsis, seizures, hypoglycaemia and feeding
difficulties [8]. In the long-term, maternal obesity has
been associated with lower offspring cognitive function
and increased risk of attention deficit hyperactivity and
other psychiatric disorders [9, 10]. Moreover, maternal
obesity is associated with adverse cardiometabolic health
in the offspring. Fetal exposure to excessive nutrients
such as maternal hyperlipidaemia and hyperglycaemia,
can result in accelerated growth, especially of adipose
tissue [7]. Larger infants with increased fat mass are
more likely to become obese children [11], and are pre-
disposed to high blood pressure, type 2 diabetes and other
metabolic dysfunctions in adulthood [12, 13]. This creates
a vicious intergenerational cycle, termed “developmental
overnutrition” [14], which may have contributed to the
increases in obesity and type 2 diabetes observed over the
recent decades.
Based on a number of observational studies, the Institute
of Medicine recommends 5–9 kg of gestational weight gain
(GWG), in obese women, for optimal maternal and infant
outcomes [15]. Exceeding recommended GWG is associ-
ated with increased risk of GDM, preeclampsia, LGA, and
caesarean in labour independent of maternal BMI [16, 17].
Mothers with excessive weight gain are less likely to lose
weight between pregnancies, and may enter further
pregnancies even more overweight [18, 19]. Further, exces-
sive GWG compounds the associations between maternal
obesity and offspring metabolic dysfunction and cognitive
problems [9, 20, 21]. However, implementation of GWG
guidelines in practice is challenging. Studies suggest
that obese women are more likely to gain an excessive
amount of weight during pregnancy than non-obese
women [22], and may require more theoretically-
designed interventions [23]. There is also an emerging
demand from prenatal care providers for effective and
reproducible intervention guidance [24].
Lifestyle interventions during pregnancy may limit
GWG, however, limited data are available to identify the
key components of intervention(s) that are responsible for
the positive outcomes [23]. A systematic review reported
that amongst diet, physical activity, and mixed approach
interventions, dietary interventions were associated with
the largest reduction in GWG (4 kg on average) and also
with improved pregnancy outcomes [25]. A UK pilot trial
of intensive behavioural intervention in obese pregnant
women suggested that there is greater potential for change
in dietary intake than in physical activity [26]. However, it
has been consistently reported from several recent rando-
mised controlled trials (RCT) that lifestyle interventions
alone have a limited effect on reducing GWG in obese
pregnant women [27–29]. Additional interventions in
combination with lifestyle interventions therefore require
evaluation in clinical trials to determine whether such
combinations can achieve improvements in GWG.
Mobile phone texting technologies are increasingly be-
ing used to assist with weight loss. A systematic review
has shown that use of mobile phone technologies in
non-pregnant populations can result in successful weight
loss with increased physical activity and improved nutri-
tion [30]. There was a high level of acceptability and
user satisfaction rating, with a significant number of par-
ticipants stating they would recommend text messaging
as a primary intervention to others [30]. A New Zealand
multi-ethnic study, in an obese non-pregnant cohort,
confirmed the feasibility of using mobile phone technol-
ogy together with behaviour change techniques. They
reported successful weight loss in participants [31]. A re-
cent pilot study of 35 overweight and obese pregnant
women reported a 2.7 kg mean GWG reduction with a
texting intervention [32].
Modification of the gut microbiome by ingestion of pro-
biotics is a novel pathway for possible intervention to pre-
vent metabolic disease. The microbiome influences energy
extraction from food [33], and satiety, inflammation, and
glucose and lipid metabolism [34–36], with potential to
reduce obesity and type 2 diabetes [37]. Probiotics are safe
in pregnancy [38, 39] and provide a simple intervention in
pill form. A randomised controlled trial of probiotics/pla-
cebo (Lactobacillus rhamnosus GG and Bifidobacterium
lactis at 1010 colony-forming units/day) and nutritional
advice in pregnant women in Finland showed an over 60%
reduction in GDM, with a prevalence of 13% in the pro-
biotic/nutrition group compared with 36% in placebo/
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nutrition group and 34% in controls [40]. In addition, a re-
duction in maternal central adiposity at 6 months postpar-
tum and a 127 g average reduction of birthweight were
demonstrated in the probiotic treatment group [41, 42].
Besides the reported efficacy of these probiotic capsule in
reducing GDM, daily probiotic yoghurt has been associ-
ated with a 40% reduction in preeclampsia [43] which is
also a common complication in obese pregnant women. A
RCT of probiotics/placebo aimed to prevent GDM in
overweight and obese women has started in Brisbane,
Australia [44], but no studies have been reported to date,
confined to obese pregnant women or in combination
with intensive dietary intervention, aimed to prevent
excessive GWG.
Pregnancy is described as a “teachable moment”
providing a finite window during which women are
more likely to undergo behavioural change if there
are perceived benefits for their offspring [45].
Accordingly, we are undertaking an innovative, ran-
domised controlled demonstration trial of probiotics
or placebo plus an intensive, culturally tailored multi-
faceted dietary intervention in obese pregnant women in
South Auckland, New Zealand. We hypothesise that in
obese pregnant women the interventions will reduce:
1) the incidence of excessive GWG; and/or 2) infant
birthweight.
Methods and design
Study design and the setting
The healthy mums and babies (HUMBA) study is a sin-
gle centre two by two factorial randomised controlled
demonstration trial (parallel groups) designed according
to CONSORT guidelines [46] and the SPIRIT guidelines
for preparation of protocols [47]. We aim to investigate
whether or not an oral probiotic capsule consisting of
Lactobacillus rhamnosus GG and Bifidobacterium lactis
BB12 at a dose of 7 × 109 colony-forming units per day
each, or a multifaceted dietary intervention, can reduce
excessive GWG and optimise infant birthweight in obese
pregnant women.
The HUMBA study is being conducted in the
multi-ethic Counties Manukau Health (CMH) region,
South Auckland, New Zealand, where 40% of preg-
nant women are obese in early pregnancy [48]. The
ethnic distribution of the birthing population (>7000
per annum) in CMH is 36% Pacific, 24% Māori, 17%
Asian, and 23% European/other [48]. There is high
socioeconomic deprivation in the region with 53% of
the women who birthed in the area in 2013 cate-
gorised as being in the lowest socioeconomic quintile
for New Zealand [48]. The perinatal mortality is
higher in CMH than in any other district health
board in the country [49]. The external review of
maternity care in CMH has iterated obesity as a major risk
factor for stillbirth in the Pacific community [49]. There is
an urgent need for effective and sustainable interventions
in this high-risk population to improve maternal and
child health.
Inclusion criteria
Women with a singleton pregnancy, BMI ≥ 30 kg/m2,
between 120 and 176 weeks of gestation and able to
provide informed written consent.
Exclusion criteria
Pre-existing diabetes or HbA1c at booking ≥ 50 mmol/mol
[50], taking probiotic supplements, known congenital
abnormality, medications or medical conditions which alter
glucose metabolism, multiple pregnancy, bariatric surgery,
and severe hyperemesis.
Randomisation
Randomisation is undertaken using a web-based proto-
col, randomize.net (http://randomize.net), using random
block sizes (minimum 4; maximum 8). For randomisa-
tion purposes, each research midwife will serve as a
proxy for ‘clinical site’ (this will enable each research
midwife to be able to dispense the randomised study
capsules at recruitment). Participants are stratified by
‘clinical site’ (n = 2) and BMI category (BMI of 30–34.9
or BMI ≥35 kg/m2) and randomly allocated in a 1:1 ratio
to dietary intervention or routine dietary advice; and 1:1
ratio to probiotic or placebo (Fig. 1).
Study interventions
1. Dietary intervention vs routine dietary advice
1.1 Dietary intervention
The multifaceted dietary intervention comprises the
following four components.
a) Encounters with nutrition advisor
The nutrition advisors are community health
workers (CHW), usually of Pacific or Māori ethnic
background, and are experienced in engaging hard-
to-reach women in maternity care in our target
population. CHW are an integral part of the health
workforce in Counties Manukau. They have been
trained in the Pacific Heart Beat Certificate of
Nutrition by the New Zealand National Heart
Foundation, which covers general nutrition as well
as complementary extra training in nutrition
during pregnancy [51]. A New Zealand registered
dietitian has developed a standard operating
procedure manual for the CHWs, and provides
support, advice and oversight of the nutritional
education package administered to participants by
the CHWs.
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The encounters include taking an initial brief
diet and physical activity history followed by
education on appropriate weight gain and in-depth
education on healthy eating. The dietary education
includes advice about: portion control, healthy food
and drink choices, limiting energy dense foods,
healthy recipes, label reading and managing cravings.
Each participant has an initial 1–1.5 h
educational session (on average at about
14 weeks’ gestation) with the CHW. Three
further 30–60 min face-to-face sessions are
planned with the CHW at two weekly intervals
and be completed by 28 weeks. Compliance with
the dietary intervention is being assessed by the
number of educational sessions participants
attend with the CHW.
A HUMBA participant handbook containing
detailed information about the suggested content
of each of the four dietary education encounter
visits is provided to women randomised to the
dietary intervention. Participants are also
encouraged to use the healthy recipes provided
in their handbook.
b) Behaviour change techniques
CHWs have received training in evaluation
methodology and counselling techniques,
including healthy conversations [52]. Behaviour
change techniques are incorporated in the
nutrition education sessions including identifying
barriers, self-monitoring, goal setting, and provid-
ing regular feedback [53]. Targets will be set for
optimal GWG at the first visit with the CHW.
Weight is measured and plotted on a personalised
GWG chart, in the participant handbook, at each
subsequent encounter.
c) Physical activity advice
Physical activity advice which is included
in the dietary intervention incorporates
Fig. 1 Overview of recruitment and randomisation in the HUMBA study
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information from the Te Wai o Rona program
(http://www.sportwaikato.org.nz/resources-
library.aspx?resource=document-resource-
category-2) [54] and the Royal College of
Obstetricians and Gynaecologists (RCOG)
guidelines for recreational exercise in pregnancy
[55]. In TeWai o Rona, there are four key physical
activity messages which are relevant to pregnant
women: 1) look for ways to be active every day,
2) increase daily exercise, 3) move more, add more
steps, and 4) reduce sedentary leisure time. The
RCOG guideline recommends that previously
sedentary women begin with 15 min of exercise
focusing on walking three times weekly and
gradually increasing to 30 min sessions four times
a week to daily [55].
d) Motivational texting
Three times weekly motivational texting, which
reinforces the educational content covered in the
face-to-face meetings with the CHW, is imple-
mented for those participants in the dietary inter-
vention with cell phones (in our recent survey of
pregnant women at CMH, 98% had a cell phone
[56]). Text messaging continues until birth and
incorporate messages about diet and physical
activity.
1.2 Routine dietary advice
These women receive current best practice advice
including a pamphlet produced by the New Zealand
Ministry of Health (Eating for Healthy Pregnant
Women) which contains dietary advice that follows
current New Zealand nutrition guidelines [57].
They also receive a pamphlet providing information
about healthy weight gain and physical activity in
pregnancy [58].
2. Probiotic/placebo intervention
Probiotic or placebo capsules are taken once daily
from enrolment between 120 and 176 weeks of
gestation until birth.
2.1 Probiotic intervention
Participants randomised to probiotic treatment will
receive probiotic capsules containing Lactobacillus
rhamnosus GG and Bifidobacterium lactis BB12
(Chr. Hansen A/S, Horsholm, Denmark) at a dose
of 7 × 109 colony-forming units per day each. Chr.
Hansen A/S make the Probio-TecÒ BG-Vcap-6.5
capsules from library colonies which are meticulously
DNA fingerprinted to ascertain the presence of
Bifidobacterium BB12 and Lactobacillus rhamnosus
GG only. The packaging and storage of the probiotics
will comply with company specifications ensuring the
quality of the product. This is the equivalent probiotic
combination that was used by Luoto et al. in the
Finnish study [40] and also being used in the ongoing
study in Queensland [44].
2.2 Placebo
Participants randomised to placebo will receive
identical capsules containing microcrystalline
cellulose and dextrose anhydrate, also supplied by
Chr. Hansen A/S, Horsholm, Denmark.
Allocation concealment and blinding
Christian Hansen has provided identically packaged can-
isters of placebo and probiotic capsules, containing 31
capsules each. AnQual Laboratories (School of Phar-
macy, University of Auckland) have labelled the canisters
using a pre-allocated random list. The kit list used to
label the canisters was generated by the Project Manager
and AnQual, using the Excel random function. This list
has secure password protection and is stored with AnQ-
ual. The Project manager is the only HUMBA staff
member with access to the probiotic/placebo allocation.
Although it will not be possible for clinical and research
staff to be blinded to the dietary intervention allocation,
the key health outcomes including GWG, infant birth-
weight and results from the oral glucose tolerance test
(OGTT), are not subject to bias.
Assessment of compliance
Compliance with the dietary intervention will be
assessed by the number of educational sessions partici-
pants attend with the CHW. Compliance with
probiotic/placebo will be assessed by the research team
via participant self-report at 28 weeks, 36 weeks and
birth visits.
Engagement for recruitment
We have a multi-pronged approach to optimise recruit-
ment including through lead maternity caregivers (self-
employed midwives), community antenatal clinics, general
practitioners, practice nurses, ultrasound clinics, commu-
nity contacts, and social media. Our research team provides
educational sessions for the health care providers to maxi-
mise reach for recruitment. Lead maternity caregivers
notify the research team about contact details of eligible
women who are interested in participating. The research
midwife arranges a time to meet the woman in a suitable
location to explain the study, confirm eligibility and obtain
informed consent.
In order to exclude women with previously unrecog-
nised Type 2 diabetes, HbA1c is measured in all partici-
pants (using the Roche cobas b 101 point-of-care system)
prior to randomisation. If HbA1c is ≥50 mmol/mol,
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women are ineligible and considered to have undiagnosed
diabetes [50]. They will be referred to the Diabetes in
Pregnancy Service at CMH. If the HUMBA point of care
HbA1c is <50 mmol/mol, then the result is not revealed
to health practitioners.
Measures/data collection
Members of the research team will meet participants at
pre-specified intervals during pregnancy (Fig. 2) to
collect outcome data, provide further supplies of
probiotic/placebo and check compliance.
Minimal data are collected with verbal consent in
referred eligible women who decline to participate in
the study. These minimal data include self-reported
weight, height, age, ethnicity and reason for their non-
participation.
1st assessment visit (120 – 17+6 weeks)
Confirmation of eligibility, informed consent, and ran-
domisation is conducted at the first assessment visit.
Comprehensive information is obtained from the woman
and her clinical records, including: demographic,
Fig. 2 Research plan flow chart for the HUMBA study. * Fasting, one-hour and two-hour glucose after 75 g glucose load. ** Women randomised
to the dietary intervention will be seen 4 times at 2–3 weekly intervals between recruitment and the 26–28 week OGTT
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socioeconomic, educational and employment data; med-
ical history; obstetric history such as parity, method of
conception, gestation and accuracy of estimated date of
delivery, previous pregnancy complications (GDM,
hypertensive disease, pre-term delivery, caesarean sec-
tion); family history of diabetes, hypertension and car-
diovascular disease; history of smoking, alcohol and
other drug use; medications and nutritional supple-
ments; probiotic food ingestion; maternal anthropomet-
rics: weight, height, waist and mid-arm circumference;
blood pressure (BP); finger-prick blood lipid testing
(Roche cobas b 101 point-of-care system); samples
collection : non-fasting blood and urine specimen for
biobank; questionnaires including: New Zealand Food
Frequency Questionnaire - Short Form [59], New Zealand
Physical Activity Questionnaire [60], Edinburgh Postnatal
Depression Scale (EPDS) [61], State-Trait Anxiety Inven-
tory (STAI) [62], and the 12-item Short-Form Health Sur-
vey (SF-12) [63]. It takes approximately 30 min to
complete these questionnaires.
2nd assessment visit (28–30 weeks)
All women in the HUMBA trial are requested to have an
OGTT at 26–28 weeks. The second assessment visit is
scheduled after the OGTT at approximately 28–30 weeks.
Weight, mid-arm circumference and BP are measured.
The food frequency, physical activity questionnaires and a
fetal movement questionnaire are completed by the par-
ticipant. The fetal movement questionnaire is adopted
from a previous study [64]. An updated medical history is
obtained by the research midwife. The OGTT results are
reported to the research team with fasting, one- and
two-hour results enabling a diagnosis of GDM by the
International Association of Diabetes in Pregnancy
Study Groups (IADPSG) criteria [65]. The maternity
care provider receives fasting and two-hour glucose
results from the OGTT as per usual clinical practice
using the New Zealand Society for the Study of
Diabetes (NZSSD) criteria [66]. Women diagnosed with
GDM by the NZSSD criteria will be referred by their
maternity care provider to the Diabetes in Pregnancy
Service (as per usual practice) and managed according
to local guidelines including postpartum testing.
HbA1c and lipid concentrations are measured by
finger prick using the Roche cobas b 101 point-of-care
system.
3rd assessment visit (36 weeks)
Weight, mid-arm circumference, BP, and HbA1c and
lipid concentrations (Roche cobas b 101 point-of-care
system) are measured. Any pregnancy complications to
date and use of antibiotics are recorded. The fetal move-
ment questionnaire and functional health and well-being
questionnaires including EPDS, STAI and SF-12 are
repeated. Maternal urine, blood, stool, toenail clippings
and hair samples are collected from consenting women
for future molecular biology studies.
4th assessment visit/post-delivery evaluation
Maternal and neonatal outcomes are collected within
72 h of birth by a research midwife. Infants are weighed
at birth (Mobile electronic baby scales, SECA 334,
Germany) and detailed anthropometric measurements
obtained by research midwives within 72 h of birth
including crown-heel length by neonatometer, head, left
mid-arm, chest and abdominal circumferences using a
lasso tape, and subscapular, triceps and supra-iliac skin-
folds by Harpenden calipers (average of 2 measurements,
or median of 3 if initial measurements differ by
>0.4 mm) [67]. Among consenting participants, infant
body compositions are measured by air displacement
plethysmography (PEA POD® Cosmed, Illinois, USA) as
soon as practical after birth. In these infants, anthro-
pometry is performed at the same time as the PEA
POD® measurement. The rest of the birth outcomes are
collected from the mothers and the babies’ clinical
records.
A short survey is administered to obtain feedback
about participation in HUMBA and the study inter-
ventions, and the fetal movement questionnaire is
repeated.
5th assessment visit (5 months postpartum)
A follow up appointment with the research midwife and
a paediatrician are scheduled at 5 months (±2 weeks)
postpartum. Maternal lifestyle and food frequency ques-
tionnaires, and infant health and well-being question-
naires are completed. Measurements of maternal BP,
weight, height, waist and mid-arm circumference, and
body composition by Bioelectrical Impedance Analysis
[68] (ImpSFB7®, ImpediMed, Brisbane, Australia) are
undertaken. Data are collected on infant feeding, aller-
gies, health and anthropometry (weight and length; head,
left mid-arm, chest and abdominal circumference; sub-
scapular, triceps and suprailiac skinfolds), and body
composition by PEA POD®, if consented. Infant feeding
behaviours are assessed using the Baby Eating Behaviour
Questionnaire (BEBQ) [69], and infant eating patterns
and nutritional intake will be determined by a food
frequency questionnaire. Timing of assessment will be
based on corrected age. Consent will be obtained for
ongoing contact when funding is obtained for further
follow up.
Primary outcomes
The primary maternal outcome is the proportion of
women with excessive GWG, defined as mean weekly
weight gain >0.22 kg between recruitment and 36 weeks
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(or weight at the closest gestation to 36 weeks’ if 36 week
weight is unavailable) [15].
The primary infant outcome is infant birthweight.
Secondary outcomes
Maternal secondary outcomes include:
 Maternal pregnancy glucose metabolism as
assessed by OGTT parameters at 26–28 weeks
[70], and HbA1c at 28 and 36 weeks and 5 months
postpartum.
 Changes in diet quality and dietary patterns
between recruitment, 28–30 weeks and 5 months
postpartum [59]
 Functional health and well-being (SF-12) at 36 weeks
and 5 months postpartum [63]
 Depression and anxiety scores at 36 weeks’ and
5 months postpartum [62, 63]
 Maternal adiposity at 5 months postpartum (assessed
by weight, BMI, waist and arm circumference and fat
mass measured by bioimpedance)
 GDM by NZSSD criteria [66]
 Pregnancy induced hypertension (preeclampsia
and gestational hypertension) [71]
 Mode of birth
 Blood lipid concentrations at 28–30 and 36 weeks’
gestation and 5 months postpartum
 Maternal feedback about participation in the study
(survey at post birth visit)
Infant secondary outcomes include:
 Neonatal anthropometry: head circumference and
length, and associated Z-scores [72]; birthweight
adjusted for length; girths (chest, arm and abdominal)
adjusted for length; subscapular, triceps and suprailiac
skin fold thickness adjusted for length; and arm
muscle area adjusted for arm length
 Neonatal body composition (via PEA POD®)
including fat mass and lean mass adjusted for
length and fat mass adjusted for lean mass
 Gestational age at birth
 LGA, by customised [73] and population [72]
references.
 Small for gestational age (SGA, <10th centile), by
customised [73] and population [72] references.
 Admission to neonatal care unit (and reason)
 Neonatal composite morbidity, including birth trauma
(fracture, brachial plexus injury, cephalohaematoma,
subgaleal haematoma), hypoxic ischaemic
encephalopathy, sepsis, respiratory distress requiring
continuous positive airway pressure support,
hypoglycaemia requiring dextrose treatment (buccal
or intravenous)
 Initiation and establishment of breast feeding,
including feeding in first two postnatal weeks
(collected by phone call at 6 weeks and
questionnaires)
 Infant anthropometry and body composition at
5 months of age, as detailed above
 Infant feeding over first 5 months (breast feeding,
formula use, complementary feeding with solids)
 Feeding behaviour as assessed by BEBQ scores [69]
 Infant Nutritional intake at 5 months, estimated
from a four day food frequency questionnaire
Other secondary outcomes include:
 Attendance at study visits
 Adherence to probiotic/placebo regime
 Cost effectiveness of the intervention
Sample size and power calculation
A total of 220 participants will be recruited. With
80% power and 100 subjects remaining in each main
intervention group (allowing 10% lost to follow-up)
we can detect: 25% reduction in excessive GWG
from 80% to 60% (based on an 80% rate of excess
weight gain in obese participants in the SCOPE
study) [16] and 227 g difference in mean birthweight
(based on CMH data; mean = 3,638, SD = 521). To allow
for the two primary outcomes an alpha of 0.025 has
been used for the power calculations (Bonferroni
approach).
Statistical analysis plan
Analyses will follow the principle of intention-to-treat.
Participants will be analysed according to the assigned
treatment group at randomisation. Statistical models will
adjust for the key randomisation stratification variable,
BMI at recruitment.
Binary endpoints will be analysed using logistic regres-
sion to estimate odds ratios for each of the interventions
(dietary intervention and probiotics). Continuous out-
comes will be modelled using generalised linear models
to estimate any changes in outcomes with the interven-
tions (dietary intervention and probiotics) compared to
their respective control groups.
Primary analyses will report marginal effects for each ran-
domised exposure, with adjustment for co-intervention,
BMI at recruitment (randomisation stratification variable),
ethnicity and sex (infant outcomes). We will also test for
interactions between the main effects (primary outcomes
only), though this pilot trial has been powered only for the
main effects.
Sensitivity analyses will be carried out according to
compliance with the study interventions (primary out-
comes); specifically these will be:
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 Those women who reported taking their probiotics
most of the time at all time points (forgot to take
1–3 per month, or greater than 1 per week but not
most days at 28 weeks, 36 weeks and birth visits).
 Those that attended at least 3 out of the 4 dietary
education sessions.
Analyses of secondary outcomes involving maternal
data collected at recruitment, 36 weeks’ and 5 months’
will be analysed using mixed methods to allow for the
repeated measures of these outcomes over time. Mea-
sures of infant body composition (whole-body fat and
fat-free mass) will be adjusted by infant sex and ethni-
city, and skinfold thickness and arm muscle area will
additionally be adjusted for infant length. For birth data,
analyses will be adjusted for gestational age at birth
(weeks). We will explore for an interaction between
intervention effect and infant sex.
For the primary outcomes a two-sided alpha level
<0.025 will indicate statistical significance (Bonferroni
adjustment). For secondary outcomes, a two-sided alpha
level <0.05 will indicate statistical significance.
Depending on the proportion and the pattern of missing
data, multiple imputation may be used to impute missing
data for some exploratory variables (secondary outcomes).
Safety monitoring
The research team will oversee and manage the project. A
Trial Steering Committee has been established that con-
tains a representative group of the named investigators
who are responsible for the conduct of the trial and will
follow CONSORT guidelines [46]. An independent com-
mittee (with no conflict of interest) has been appointed
with established terms of reference to serve as the Data
Safety and Monitoring Committee (DSMC). The DSMC
includes experts in the fields of obstetrics, neonatology
and epidemiology/statistics with experience in perinatal
trials. They will assess the progress of the trial and review
reports of serious adverse events and adverse events.
Serious adverse events are defined as maternal death,
maternal admission to intensive care unit, fetal death, neo-
natal death or death up to primary hospital discharge, stage
2–3 neonatal encephalopathy, and any other serious adverse
event that the principal or local lead investigator believes
should be referred for independent review by the DSMC.
The DSMC will classify serious adverse events as to
the likelihood of a causative association with the study
intervention: no, unlikely, possible, or probable. The
DSMC can request unblinding if there is any safety con-
sideration related to the probiotic/placebo intervention.
Data management
Data will be collected in a timely fashion and entered
directly into the web-based REDCap™ [74] study database
using mobile tablets. Data are actively monitored by a data
monitor following the Data Resolution Workflow pro-
duced by REDCap™ [74]. Electronic case record forms
(CRFs) will be identified only by a study identification
number (ID), with consent forms and identifying informa-
tion stored in a separate, restricted database. In rare cases,
when paper CRFs are used they will be coded using the
study ID number, ensuring confidentiality of participants.
All paper CRFs will be stored securely in locked cabinets
for 10 years and access to all electronic data will be pass-
word protected and restricted to researchers directly
involved with the study.
No interim analysis is planned.
Discussion
This two by two factorial design randomised controlled
demonstration trial aims to reduce excessive GWG and
optimise infant birthweight in a multi-ethnic sample of
obese pregnant women. This RCT will inform whether a
multifaceted dietary intervention and or probiotic treat-
ment, are feasible interventions for obese pregnant
women in the muti-ethnic CMH region. If successful,
either one or both of the interventions are applicable to
future clinical practice. It may also inform the design of a
larger-scale intervention study for obese pregnant women
that is powered to investigate pregnancy complications.
Dissemination policy
We will publish the results of HUMBA in scientific jour-
nals and present the results at relevant conferences lo-
cally and internationally. Our publications will also be
available on the HUMBA study website, and will be
shared by email with participants who have consented to
receive a copy of the findings. Our multidisciplinary
team of investigators will disseminate research findings
widely via their clinical networks, including giving semi-
nars and presentations to health professionals and com-
munity groups. We will utilise newsletters of relevant
professional bodies to further disseminate research findings.
Findings from HUMBA will also be incorporated into the
relevant Cochrane systematic reviews thereby increasing
dissemination both locally and internationally.
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